|4Feb 22, 9:09 PM ET

OncoCyte Corp 4

4 · OncoCyte Corp · Filed Feb 22, 2017

Insider Transaction Report

Form 4
Period: 2017-02-17
ANNETT WILLIAM
DirectorPresident and CEO
Transactions
  • Award

    Option to Purchase Common Stock

    2017-02-17+225,000250,000 total
    Exercise: $4.70Exp: 2027-02-16Common Stock (225,000 underlying)
Holdings
  • Option to Purchase Common Stock

    Exercise: $3.06Exp: 2026-02-15Common Stock (250,000 underlying)
    250,000
  • Option to Purchase Common Stock

    Exercise: $2.20Exp: 2025-06-15Common Stock (605,000 underlying)
    605,000
  • Option to Purchase Common Stock

    Exercise: $2.20Exp: 2025-01-08Common Stock (5,000 underlying)
    5,000
Footnotes (4)
  • [F1]One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
  • [F2]One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
  • [F3]One quarter of the options vested on June 15, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
  • [F4]Became exercisable in two equal installments based upon continued service on the board of directors from the date of grant on January 9, 2015.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION